14.70
-0.31 (-2.07%)
| Previous Close | 15.01 |
| Open | 15.07 |
| Volume | 182,191 |
| Avg. Volume (3M) | 390,485 |
| Market Cap | 911,832,128 |
| Price / Book | 3.23 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -0.790 |
| Total Debt/Equity (MRQ) | 0.21% |
| Current Ratio (MRQ) | 29.71 |
| Operating Cash Flow (TTM) | -41.26 M |
| Levered Free Cash Flow (TTM) | -27.93 M |
| Return on Assets (TTM) | -11.97% |
| Return on Equity (TTM) | -16.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | GH Research PLC | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.5 |
| Technical Oscillators | -2.0 |
| Average | 0.13 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.88% |
| % Held by Institutions | 68.90% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Highvista Strategies Llc | 30 Sep 2025 | 241,894 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (HC Wainwright & Co., 376.19%) | Buy |
| Median | 40.00 (172.11%) | |
| Low | 32.00 (Needham, 117.69%) | Buy |
| Average | 44.60 (203.40%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 15.74 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citizens | 06 Mar 2026 | 42.00 (185.71%) | Buy | 15.93 |
| Needham | 06 Mar 2026 | 32.00 (117.69%) | Buy | 15.93 |
| 06 Jan 2026 | 29.00 (97.28%) | Buy | 14.12 | |
| HC Wainwright & Co. | 02 Mar 2026 | 70.00 (376.19%) | Buy | 16.01 |
| RBC Capital | 23 Jan 2026 | 40.00 (172.11%) | Buy | 16.73 |
| Canaccord Genuity | 06 Jan 2026 | 39.00 (165.31%) | Buy | 14.12 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Jan 2026 | Announcement | GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026 |
| 02 Jan 2026 | Announcement | GH Research to Announce IND Status for GH001 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |